[Ip-health] National Pharmaceutical Pricing Authority slashes stent prices by up to 85%

K.M. Gopakumar kumargopakm at gmail.com
Tue Feb 14 01:53:52 PST 2017


National Pharmaceutical Pricing Authority slashes stent prices by up to 85%Rema
Nagarajan | TNN | Updated: Feb 14, 2017, 09.01 AM IST
Highlights

   - The ceiling price of drug eluting stents (DES) and bioresorbable
   stents at Rs 30,000 and that of bare metal stents have been fixed at Rs
   7,500.
   - The prices will be effective from notification on Feb 14.
   - This comes as a huge relief to lakhs of patients who have to undergo
   coronary angioplasty.


The National Pharmaceutical Pricing Authority
<http://timesofindia.indiatimes.com/topic/National-Pharmaceutical-Pricing-Authority>
on Monday fixed the ceiling price of drug eluting stents
<http://timesofindia.indiatimes.com/topic/drug-eluting-stents> (DES)
and bioresorbable
stents <http://timesofindia.indiatimes.com/topic/bioresorbable-stents> at
Rs 30,000 and that of bare metal stents at Rs 7,500. The prices will be
effective from notification on February 14.

This comes as a huge relief to lakhs of patients who have to undergo coronary
angioplasty+ to insert stents to open up clogged arteries. Over six lakh
stents were estimated to have been used in angioplasties in India in 2016.

The cost of a drug eluting stent currently ranges between Rs 24,000 and Rs
1.5 lakh and that of a bioresorbable stent is Rs 1.7 lakh to Rs 2 lakh.
Over 95% of stents used in India are drug eluting.

According to data submitted by stent companies to the NPPA+ , the average
manufacturing cost of a DES for a domestic company is about Rs 8,000 and
prices of imported DES start at about Rs 5,000. The NPPA also revealed that
a stent could cost the patient over ten times by the time it moved from the
manufacturer to the patient.

The data showed that hospitals made the maximum profit on stents+ , marking
up prices by as much as 650% in some cases. Many hospitals saw stents as
part of their revenue stream and made huge profits on them and hospital
groups had strongly opposed price control on stents.

With the new notification, hospitals will have to bill stents separately.
All hospitals will also have to follow Para 24 (4) of the Drug Price
Control Order (DPCO) 2013 which states: "Every retailer and dealer shall
display the price list and the supplementary price list, if any, as
furnished by the manufacturer, on a conspicuous part of the premises where
he carries on business in a manner so as to be easily accessible to any
person wishing to consult the same."

The health ministry notified the inclusion of stents in the National List
of Essential Medicines (NLEM) on July 19 last year, after the Delhi High
Court sought action on a public interest petition seeking price control on
stents.


Five months later, on Dec 21, the department of pharmaceuticals notified
stents in schedule-I of the DPCO 2013 clearing the way for price fixation.

"If this is true, this is definitely heart-warming news for millions of
Indians. We look forward to immediate implementation," said Malini Aisola
<http://timesofindia.indiatimes.com/topic/Malini-Aisola> of the All India
Drug Action Network
<http://timesofindia.indiatimes.com/topic/All-India-Drug-Action-Network>
(AIDAN).

http://timesofindia.indiatimes.com/india/stent-prices-slashed-by-up-to-85/articleshow/57136127.cms
?



More information about the Ip-health mailing list